✓ checked
trust me, bro:
here is the receipt.
the claim
As of 2026, no drug has been approved by the US FDA specifically to treat vascular dementia.
the verdict
INSUFFICIENT LEANING
Recorded sources
2 sources for · 0 against
Is it true that as of 2026, no drug has been approved by the US FDA specifically to treat vascular dementia?
Unclear. One review states that no specific drugs for vascular cognitive impairment and dementia are currently available and that FDA-approved therapies are absent, but it predates 2026; a 2026 stroke organization statement treats vascular dementia treatment as a potential future avenue rather than an approved indication. Neither source directly confirms the claim as of 2026.
Verdict: PARTIAL LEAN · 2 sources for, 0 against · Last checked
Evidence for · 2
Get citation
Druggable genome‐wide Mendelian randomization analysis identifies potential treatment targets in vascular dementia - PMC Lock. (n.d.). pmc.ncbi.nlm.nih.gov. https://doi.org/10.1002/trc2.70258
See more details
More for · 1
Get citation
GJ, B., S, D., FM, E., F, G., GK, H., TM, H., M, I., JD, I., H, J., A, N., ST, P., R, P., JA, S., C, S., EE, S., P, V., JM, W., AJ, W., DM, W., & AH, H. (2026). The vascular contribution to dementia: World Stroke Organization scientific statement.. doi.org. https://doi.org/10.1177/17474930261470506
Receipt History
Anyone with this link can read the claim and its public receipt, including any
personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check
or guarantee a response time.
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work
Terms · Privacy · How verdicts work